Published in Gastroenterology on June 01, 2002
CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol (2007) 1.15
Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients. Gastroenterology (2003) 0.76
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology (2002) 3.96
Surviving AIDS, and AIDS dementia. AIDS Read (2006) 1.39
Sustained release of microbicides by newly engineered vaginal rings. AIDS (2009) 1.38
A medical miracle, but for how long? AIDS Read (2005) 1.38
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol (2012) 1.33
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2009) 1.16
The effects of Eculizumab on the pathology of malignant atrophic papulosis. Orphanet J Rare Dis (2013) 1.11
WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am J Pathol (2008) 1.09
Translating ideas into action: two new features initiated by Translational Research, as genomics enters the clinics. Transl Res (2011) 1.06
Accessibility and longevity of Internet citations in a clinical AIDS journal. AIDS Patient Care STDS (2005) 0.95
Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir. Biochem Biophys Res Commun (2011) 0.90
HIV and the lung in the HAART era. AIDS Read (2005) 0.89
Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol (2004) 0.88
Making HIV testing routine. AIDS Read (2007) 0.81
Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood (2013) 0.80
The role of prisons in dissemination of HIV and hepatitis. AIDS Read (2005) 0.80
Transforming growth factor-β1-mediated cardiac fibrosis: potential role in HIV and HIV/antiretroviral therapy-linked cardiovascular disease. AIDS (2016) 0.79
No more boring science, no more waste in clinical trials. Transl Res (2008) 0.78
Translating translational research. Transl Res (2006) 0.78
Impact of HAART on HIV-linked malignancies. AIDS Read (2003) 0.78
Suppressing HIV transmission--through behavior and biology. AIDS Read (2006) 0.77
Drug resistance among HIV and its "friends". AIDS Read (2003) 0.77
Treating HIV infection with one pill per day. AIDS Patient Care STDS (2006) 0.77
Hepatitis A and B virus immunization in HIV-infected persons. AIDS Read (2006) 0.77
Modeling metabolic effects of the HIV protease inhibitor ritonavir in vitro. Am J Pathol (2007) 0.76
Non-AIDS-defining malignancies and HAART. AIDS Read (2007) 0.75
The medical miracle: more questions. AIDS Read (2005) 0.75
Endothelial cell activation and apoptosis in the thrombotic microangiopathies. Br J Haematol (2004) 0.75
HCV infection in the setting of HIV: prevalence, disease, treatment. AIDS Read (2006) 0.75
Repetitive mucosal exposure to human herpesvirus-8 and protection against its penile-vaginal transmission. J Infect Dis (2003) 0.75
HIV epidemics, HIV therapeutics: recent trends. AIDS Read (2003) 0.75
Antiretroviral suppression of HIV in the context of persistently low CD4 counts: new insights. AIDS Read (2007) 0.75
More hot topics in HIV/AIDS. AIDS Read (2002) 0.75
T-20: a model for novel anti-HIV drugs in development. AIDS Read (2002) 0.75
HIV therapeutics in children and adults and their side effects. AIDS Read (2004) 0.75
Two areas in urgent need of HIV-related prevention: injection drug use and extensively drug-resistant TB. AIDS Read (2006) 0.75
Two months of AIDS reports: critical lessons for HIV biology and medicine. AIDS Read (2008) 0.75
Prevention vs. treatment and the future of HIV medical care. AIDS Patient Care STDS (2002) 0.75
Treating HIV: when to start, who should treat, and still missing many. AIDS Read (2008) 0.75
Changes in HIV-related diseases and the future of HIV medical care. AIDS Read (2002) 0.75
The "missing face" of AIDS. AIDS Read (2007) 0.75
Durability of clinical responses to anti-HIV therapies. AIDS Read (2008) 0.75
9th National Retrovirus Conference: new treatments, new choices. AIDS Patient Care STDS (2002) 0.75
HIV therapy, guided by CD4 counts. AIDS Read (2006) 0.75
XV International AIDS Conference: science versus political science. AIDS Read (2004) 0.75
Multidrug-resistant HIV. AIDS Read (2005) 0.75
Results of the first phase 3 trial of an AIDS vaccine. AIDS Read (2003) 0.75
Antiretrovirals in the pipeline: anticipated updates. AIDS Read (2005) 0.75
Hot topics in AIDS therapeutics. AIDS Read (2002) 0.75
Possible HIV "super-strain" in New York City; new human T-lymphotropic viruses identified in Africa. AIDS Read (2005) 0.75
AIDS vaccines, immunology, and what we have learned. AIDS Read (2002) 0.75
Combined factor V and factor VIII deficiency: a report of a case, genetic analysis, and response to desmopressin acetate. Clin Adv Hematol Oncol (2012) 0.75
Learn a new trade: repairing broken pipelines. Transl Res (2008) 0.75
Medication adherence rates and drug-resistant HIV: new data. AIDS Read (2003) 0.75
Pivotal moments in HIV treatment: the 14th CROI. AIDS Read (2007) 0.75
HIV variants of low frequency may have a big impact. AIDS Read (2007) 0.75
HIV therapeutics, continued: another HIV protease inhibitor approved. AIDS Read (2003) 0.75
New trends in HIV disease worldwide. AIDS Read (2003) 0.75
Stem cell ping-pong: the politics of science. Transl Res (2010) 0.75
Recent studies of sexual transmission of HIV. AIDS Read (2006) 0.75
HIV therapeutics: points from the recent literature. AIDS Read (2003) 0.75
Yet another World AIDS Day. AIDS Read (2006) 0.75
Centennial celebration of translational research: the Journal of Laboratory and Clinical Medicine. Transl Res (2014) 0.75
Immune restoration and HAART: new clinical and in vitro data. AIDS Read (2002) 0.75
Debating global HIV incidence. AIDS Read (2006) 0.75
"Scientific gambles": AIDS microbicides and vaccines. AIDS Read (2002) 0.75
Use of bone marrow examination in HIV/AIDS. AIDS Read (2005) 0.75
A cure for AIDS? AIDS Read (2007) 0.75
Support for translational research: exhausting all the possibilities. Transl Res (2013) 0.75
Update from Seattle: the 9th Annual Retrovirus Conference. AIDS Read (2002) 0.75
Bridging the gap between "ABC" and an AIDS vaccine. AIDS Read (2006) 0.75
Update: a 25th anniversary and a UN global AIDS summit. AIDS Read (2006) 0.75
Mexico City: a call for "universal action now". AIDS Read (2008) 0.75
HAART, hepatitis C, activated T cells, and mortality. AIDS Read (2003) 0.75
HIV immune pathogenesis: an update from CROI. AIDS Read (2005) 0.75
Know your epidemic. AIDS Read (2007) 0.75
Compartmentalizing AIDS. AIDS Read (2008) 0.75
RNA silencing: a new therapeutic strategy against HIV. AIDS Read (2003) 0.75
Report from the National HIV Prevention Conference. AIDS Read (2005) 0.75
Therapeutic vaccination for HIV disease. AIDS Read (2003) 0.75
Stroke and anemia in HIV/AIDS. AIDS Read (2004) 0.75
Biomedical methods for HIV prevention: new setbacks. AIDS Read (2008) 0.75
CD4 cell depletion in AIDS: models for novel therapies. AIDS Read (2002) 0.75
Bullet points: new topics in HIV/AIDS. AIDS Patient Care STDS (2002) 0.75
Women and HIV. AIDS Read (2007) 0.75
Leads from the Third International AIDS Society conference. AIDS Read (2005) 0.75
Treating HIV infection without antiretrovirals; preventing HIV infection with them. AIDS Read (2004) 0.75
Seeking a cure for AIDS. AIDS Read (2008) 0.75
Highlights of a year in AIDS. AIDS Read (2007) 0.75
Recent highlights in clinical AIDS research. AIDS Read (2008) 0.75
Mortality among patients with HIV infection in the HAART era. AIDS Read (2004) 0.75
Simplifying HIV therapeutics, and the global treatment of AIDS. AIDS Read (2003) 0.75
Preventing sexually transmitted infections, 2008. AIDS Read (2008) 0.75
Curb your enthusiasm. Transl Res (2007) 0.75
Pulse therapy. AIDS Read (2004) 0.75
Start anti-HIV treatment early, in adults and infants. AIDS Read (2009) 0.75
HPV-linked malignancy and the potential of vaccine-based prevention. AIDS Read (2005) 0.75
Identifying and modifying barriers to HIV testing and prevention. AIDS Read (2002) 0.75
Once-daily dosing and the treatment of HIV disease. AIDS Read (2006) 0.75